ADMA Biologics, Inc. (ADMA): A Bull Case Theory
We came across a bullish thesis on ADMA Biologics, Inc. on Stockmindsweb’s YouTube Channel. In this article, we will summarize the bulls’ thesis on ADMA.
Adma Biologics Inc. (ADMA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sachem Head Capital Scott Ferguson | 11,375,000 | $207,480,000 | +27% | 4.86% |
| 2. | Caligan Partners David Johnson | 3,012,508 | $54,948,146 | +15% | 4.52% |
| 3. | Ranger Investment Management Conrad Doenges (Cio) | 2,300,905 | $41,968,507 | -2% | 2.88% |
| 4. | Fundsmith LLP Terry Smith | 2,102,054 | $38,341,465 | 0.22% | |
| 5. | Renaissance Technologies Jim Simons | 1,532,621 | $27,955,007 | -45% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.71 | 130,000 | $482,144.00 | 443,265 | 2023-08-30 | Filing | |
| $3.90 | 25,000 | $97,500.00 | 277,401 | 2023-08-24 | Filing | |
| $2.86 | 6,993 | $19,999.98 | 1,034,825 | 2022-12-09 | Filing | |
| $2.86 | 14,982 | $42,848.52 | 1,143,426 | 2022-12-09 | Filing | |
| $2.86 | 14,983 | $42,851.38 | 2,203,708 | 2022-12-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.08 | 6,000 | $96,480.00 | 2,284,379 | 2026-02-17 | Filing | |
| $16.08 | 15,000 | $241,200.00 | 2,290,379 | 2026-02-17 | Filing | |
| $19.79 | 6,000 | $118,740.00 | 2,007,850 | 2025-12-15 | Filing | |
| $19.79 | 15,000 | $296,850.00 | 2,013,850 | 2025-12-15 | Filing | |
| $16.00 | 6,000 | $96,000.00 | 2,013,850 | 2025-11-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,333,325 | $662,719,847 | 0.01% | |
| 2. | 20,854,669 | $380,389,162 | 0.01% | |
| 3. | 13,597,259 | $248,014,004 | 0.01% | |
| 4. | 11,785,202 | $214,962,084 | 0.03% | |
| 5. | 6,992,907 | $127,550,624 | 0.53% |
News See All
15 Stocks That Could Mint Millionaires in 2026
For more than a century, investing in the stock market in the United States has represented one of the most accessible paths to generating substantial wealth for the amateur investor, with a long and ...
ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics Third Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, November 5 2025.
Renaissance Small Cap Growth Strategy Added ADMA Biologics (ADMA) to Its Portfolio in Q2
Renaissance Investment Management, an investment management company, released its Q2 2025 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here.
ADMA Biologics, Inc. (ADMA): A Bull Case Theory
We came across a bullish thesis on ADMA Biologics, Inc. on Archive Invest’s Substack by Felix. In this article, we will summarize the bulls’ thesis on ADMA.
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics Second Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, August 6, 2025.
Heavy Insider Selling at ADMA Biologics Despite Earnings Strength
Headquartered in New Jersey, ADMA Biologics, Inc. (NASDAQ:ADMA) is the only U.S.-based producer of plasma-derived immunoglobulin therapies.
13 Best Low Risk High Growth Stocks to Buy
The current market is witnessing political chess moves, which are also affecting policy changes.
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios
ADMA Biologics fell by 14.7 percent week-on-week, closing Friday at $17.74 versus the $20.81 on June 13, as investors took path from three of its executives’ recent disposition of shares in the company...
Hedge Fund Resource Center